|
Field
Last Published
|
Before
July 18, 2019 06:19 PM
|
After
July 30, 2019 04:59 PM
|
|
Field
Primary Outcomes (End Points)
|
Before
Transdiagnostic Therapy approach is practical in increasing emotion regulation and decreasing the difficulties in Emotion Regulation (DER).
As was outlined in previous sections, considerable evidence has revealed that Emotional problems are common in PWMS with distressing influences as much as physical problems.
|
After
Transdiagnostic Therapy approach is practical in increasing emotion regulation (ERQ scores) and decreasing the difficulties in Emotion Therapy was effective in decreasing anxiety and depression symptoms and Difficulties in Emotion Regulation among subjects in the post-test stage
|
|
Field
Experimental Design (Public)
|
Before
The inclusion criteria included:
1. Diagnosis of MS for three years or more
2. Fluent in Persian, at least 18 years of age
4. Received at least one current diagnostic of a valid depression disorder and an anxiety disorder on Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth. Edition Axis I Disorders.
4. Received at least one self-report score without the cut-off range specified for screening measure (The Intolerance of Uncertainty Scale-Short Form (IUS-12), Anxiety Severity and Impairment Scale (OASIS), ODSIS, the Geriatric Depression Scale, the Penn State Worry Questionnaire (PSWQ), in addition to, Received at least one self-report score without the cut-off range specified for emotional screening measure :
Difficulties in Emotion Regulation Scale (DERS), the Positive and Negative Affect Schedule (PANAS), the Southampton Mindfulness Questionnaire (SMQ), and Emotion Regulation Questionnaire (ERQ-R).
5. Willing to participate in the research.
6. Fill and signature consent
7. Medical MS agreement for participation
The motive element plays an essential role in this treatment due to the relative difficulty of this treatment method. Therefore, this treatment was administered to those who were conscious of the content of this therapy and motivated to cope with its challenges.
Exclusion criteria included
1. The initial diagnosis of other psychiatric diagnoses, compensatory behaviors or cleansing,
2. Other Chronic physical illnesses (such as insulin-dependent diabetes and chemotherapy for cancer)
3. Pregnancy or lactation,
4. Evidence of current or past schizophrenia, psychosis, or organic mental disorder, bipolar disorder, or organic mental disorder
6. Drug abuse history or drug dependence except for nicotine
7. Absenteeism for more than three sessions
8. Receiving psychological interventions during one last year.
9. Presence of comorbid neurological disorders such as Alzheimer, Parkinson's disease, Dementia
|
After
The inclusion criteria included:
1. Diagnosis of MS for three years or more
2. Fluent in Persian, at least 18 years of age
4. Received at least one current diagnostic of a valid depression disorder and an anxiety disorder on Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, fourth. Edition Axis I Disorders.
5. Received at least one self-report score without the cut-off range specified for screening measure, Anxiety Severity and Impairment Scale (OASIS), ODSIS, the Geriatric Depression Scale, the Penn State Worry Questionnaire (PSWQ), in addition to, Received at least one self-report score without the cut-off range specified for emotional screening measure :
Difficulties in Emotion Regulation Scale (DERS), the Positive and Negative Affect Schedule (PANAS), the Southampton Mindfulness Questionnaire (SMQ), and Emotion Regulation Questionnaire (ERQ-R).
5. Willing to participate in the research.
6. Fill and signature consent
7. Medical MS agreement for participation
The motive element plays an essential role in this treatment due to the relative difficulty of this treatment method. Therefore, this treatment was administered to those who were conscious of the content of this therapy and motivated to cope with its challenges.
Exclusion criteria included
1. The initial diagnosis of other psychiatric diagnoses, compensatory behaviors or cleansing,
2. Other Chronic physical illnesses (such as insulin-dependent diabetes and chemotherapy for cancer)
3. Pregnancy or lactation,
4. Evidence of current or past schizophrenia, psychosis, or organic mental disorder, bipolar disorder, or organic mental disorder
6. Drug abuse history or drug dependence except for nicotine
7. Absenteeism for more than three sessions
8. Receiving psychological interventions during one last year.
9. Presence of comorbid neurological disorders such as Alzheimer, Parkinson's disease, Dementia
|
|
Field
Randomization Method
|
Before
computerized
|
After
computerized The block size of 6
|
|
Field
Planned Number of Observations
|
Before
400 women
|
After
250 women
|
|
Field
Sample size (or number of clusters) by treatment arms
|
Before
The sample size was calculated using the Cohen formula to measure the effectiveness of the interven0tion (32). Taking into account the confidence of 0.95 and the test power of .90, the results of this formula showed that 26 people are required per group. Given the probability of quitting the research and the available options, this paper was conducted on two groups of 32persons (in a total of 64 people) selected using the purposeful sampling method.
At last, 64 patients, met all inclusion criteria, were assigned to treatment and control groups using computer-generated random numbers. The treatment sessions instructed by clinical specialists holding a valid certificate on Transdiagnostic Therapy. We defined the Zero session as an explanation of objectives in individual assignments. The researcher explained the process to participants and attracted their satisfaction. Having obtained informed written consent from all participants filled up the researcher-made demographic questionnaire. All patients were asked not to change their lifestyle during the study and continue their daily routines, exercise, diet, and medications.
|
After
The sample size was calculated using the Cohen formula to measure the effectiveness of the interven0tion (32). Taking into account the confidence of 0.95 and the test power of .90, the results of this formula showed that 26 people are required per group. Given the probability of quitting the research and the available options, this paper was conducted on two groups of 32persons (in a total of 64 people) selected using the purposeful sampling method.
At last, 64 patients, met all inclusion criteria, were assigned to treatment and control groups using computer-generated random numbers.
|
|
Field
Power calculation: Minimum Detectable Effect Size for Main Outcomes
|
Before
0.6
|
After
The power analysis was, and a large effect size (f = 0.4) ). using an alpha of 0.05, a power of 0.80, to determine the sample size required to detect a small to moderate interaction effect (f = 0.45) between group and time
|
|
Field
Keyword(s)
|
Before
Education, Other
|
After
Education, Health, Other
|
|
Field
Intervention (Hidden)
|
Before
|
After
1 Module1 Setting Goals and Maintaining Motivation (1 session)
2 Module2 Understanding Emotions (1– 2 sessions)
3 Module3 Mindful Emotion Awareness (1– 2 sessions) Core module
4 Module4 Cognitive Flexibility (1– 2 sessions) Core module
5 Module5 Countering Emotional Behaviors (1– 2 sessions) Core module
6 Module6 Understanding and Confronting Physical Sensations (session) Core module
7 Module7 Emotion Exposures (4– 6 sessions) Core module
8 Module8 Recognizing Accomplishments and Looking to the Future
|